A Comprehensive Systematic Review of The Effectiveness of Rapid Diagnostic Tests for Tuberculosis in Resource Limited Settings
Keywords:
Tuberculosis, rapid diagnostic tests, Xpert MTB/RIF, resource-limited settings, diagnostic accuracy, drug resistanceAbstract
Introduction: Tuberculosis (TB) remains a leading cause of mortality in resource-limited settings, where conventional diagnostic methods such as smear microscopy have suboptimal sensitivity and cannot detect drug resistance. Rapid diagnostic tests (RDTs) offering results within hours may address these limitations, but their effectiveness across diverse settings requires comprehensive evaluation.
Methods: This review synthesized evidence from 126 studies conducted in low- and middle-income countries across Africa, Asia, and South America. Studies evaluating RDTs for active TB diagnosis against reference standards (culture, molecular tests, or clinical diagnosis) were included. Data extraction covered diagnostic accuracy, drug resistance detection, speed, implementation feasibility, cost factors, and clinical impact.
Results: Xpert MTB/RIF demonstrated pooled sensitivity of 88-89% and specificity exceeding 98%, with substantial variation by smear status (98% in smear-positive vs 55-77% in smear-negative). Truenat assays showed comparable performance (90.6% sensitivity, 95.7% specificity), while TB-LAMP demonstrated 80% sensitivity and 98% specificity. Urine LAM testing achieved 66.7% sensitivity in severely immunocompromised HIV patients (CD4<50). For rifampicin resistance detection, Xpert MTB/RIF showed 94-95% sensitivity and 98% specificity. Time to results reduced from weeks to hours, with Xpert delivering results in <2 hours versus 16-30 days for culture. Implementation increased bacteriologically confirmed cases by 23-39% and reduced time to MDR-TB treatment from months to 22 days.
Discussion: RDTs substantially improve TB detection over microscopy, particularly for smear-negative and drug-resistant cases. However, mortality benefits remain inconsistent, reflecting effective empirical treatment in control arms and persistent challenges in linkage to care. Cost and infrastructure requirements pose implementation barriers.
Conclusion: RDTs are effective for TB diagnosis in resource-limited settings, but optimal impact requires integration into strengthened health systems with reliable treatment linkage.
References
A. Bojang, F. Mendy, L. Tientcheu, J. Otu, M. Antonio, B. Kampmann, S. Agbla, and J. Sutherland. “Comparison of TB-LAMP, GeneXpert MTB/RIF and Culture for Diagnosis of Pulmonary Tuberculosis in The Gambia.” Journal of Infection, 2016.
A. David, L. Singh, P. da Silva, K. Peloakgosi-Shikwambani, Z. Nsingwane, V. Molepo, W. Stevens, and L. Scott. “Diagnostic Accuracy of the Cobas MTB and Cobas MTB/RIF-INH Assays on Sputum and the Cobas MTB Assay on Tongue Swabs for Mycobacterium Tuberculosis Complex Detection in Symptomatic Adults in South Africa.” medRxiv, 2025.
A. Esmail, P. Randall, S. Oelofse, M. Tomasicchio, A. Pooran, R. Meldau, E. Makambwa, et al. “Comparison of Two Diagnostic Intervention Packages for Community-Based Active Case Finding for Tuberculosis: An Open-Label Randomized Controlled Trial.” Nature Network Boston, 2023.
A. Gupta-Wright. “Improving TB Diagnosis in People Living with HIV.” Public Health Action, 2020.
A. Hamid Salim, K. J. Aung, M. Hossain, and A. Van Deun. “Early and Rapid Microscopy-Based Diagnosis of True Treatment Failure and MDR-TB.” The International Journal of Tuberculosis and Lung Disease, 2006.
A. Muwonge, Sydney Malama, B. M. D. Bronsvoort, D. Biffa, W. Ssengooba, and E. Skjerve. “A Comparison of Tools Used for Tuberculosis Diagnosis in Resource-Limited Settings: A Case Study at Mubende Referral Hospital, Uganda.” PLoS ONE, 2014.
A. Ojo, S. Adebajo, O. Ojo, A. Ajibola, D. Ojo, O. Ejilude, and W. Ike. “COMPARATIVE ASSESSMENT OF DIFFERENT DIAGNOSTIC TECHNIQUES IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS IN SUSPECTED CASES OF TUBERCULOSIS.” Journal of Natural Sciences, Engineering and Technology, 2021.
A. Page, E. Ardizzoni, M. Lassovsky, B. Kirubi, D. Bichkova, A. Pedrotta, C. Lastrucci, R. de la Tour, M. Bonnet, and F. Varaine. “Routine Use of Xpert® MTB/RIF in Areas with Different Prevalences of HIV and Drug-Resistant Tuberculosis.” The International Journal of Tuberculosis and Lung Disease, 2015.
A. Penn-Nicholson, S. Georghiou, N. Ciobanu, M. Kazi, M. Bhalla, A. David, F. Conradie, et al. “Clinical Evaluation of the Xpert MTB/XDR Assay for Rapid Detection of Isoniazid, Fluoroquinolone, Ethionamide and Second-Line Drug Resistance: A Cross-Sectional Multicentre Diagnostic Accuracy Study.” medRxiv, 2021.
———, et al. “Detection of Isoniazid, Fluoroquinolone, Ethionamide, Amikacin, Kanamycin, and Capreomycin Resistance by the Xpert MTB/XDR Assay: A Cross-Sectional Multicentre Diagnostic Accuracy Study.” Lancet. Infectious Diseases (Print), 2021.
A. Penn-Nicholson, S. N. Gomathi, C. Ugarte-Gil, A. Meaza, E. Lavu, P. Patel, B. Choudhury, et al. “A Prospective Multicentre Diagnostic Accuracy Study for the Truenat Tuberculosis Assays.” European Respiratory Journal, 2021.
A. Pooran, G. Theron, L. Zijenah, D. Chanda, P. Clowes, Lawrence Mwenge, F. Mutenherwa, et al. “Point of Care Xpert MTB/RIF Versus Smear Microscopy for Tuberculosis Diagnosis in Southern African Primary Care Clinics: A Multicentre Economic Evaluation.” Lancet Global Health, 2019.
A. Rachow, Alimuddin Zumla, N. Heinrich, G. Rojas-Ponce, B. Mtafya, K. Reither, E. Ntinginya, et al. “Rapid and Accurate Detection of Mycobacterium Tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study.” PLoS ONE, 2011.
A. Rachow, P. Clowes, E. Saathoff, B. Mtafya, E. Michael, E. Ntinginya, Dickens Kowour, et al. “Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study.” Clinical Infectious Diseases, 2012.
A. Raj, S. Baliga, M. Shenoy, B. Dhanashree, P. Mithra, Smitha K. Nambiar, and L. Sharon. “Validity of a CB-NAAT Assay in Diagnosing Tuberculosis in Comparison to Culture: A Study from an Urban Area of South India.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020.
A. Tiamiyu, G. Iliyasu, F. Dayyab, Z. Habib, S. Tambuwal, Habibu Galadanci, S. Bwala, L. Lawson, and A. Habib. “Evaluation of GeneXpert MTB/RIF as a Diagnostic Tool in Patients with Sputum Smear-Negative TB in a High HIV Burden Region in Nigeria.” Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020.
A. V. Khatawkar, Nagaraj Talikot, Prashant Kumar Malkiwadeyar, Md. Juned Md. Juned, V. Hubballi, Ganeshgouda Majigoudra, N. MohithH., and S. Potkar. “THE STUDY OF UTILITY OF CBNAAT IN DIAGNOSING PULMONARY TUBERCULOSIS IN HIV POSITIVE PATIENTS IN NORTH KARNATAKA.” Journal of Evidence Based Medicine and Healthcare, 2019.
A. V. Rie, L. Page-Shipp, Colleen F Hanrahan, Kathryn Schnippel, H. Dansey, J. Bassett, Kate Clouse, L. Scott, Wendy S. Stevens, and Ian Sanne. “Point-of-Care Xpert® MTB/RIF for Smear-Negative Tuberculosis Suspects at a Primary Care Clinic in South Africa.” The International Journal of Tuberculosis and Lung Disease, 2013.
Alain Farra, Karen Koula, B. Jolly, H. Gando, Louis Médart Ouarandji, C. Mossoro-Kpinde, A. Manirakiza, Jean-Pierre Simelo, and Jean de Dieu Iragena. “Effectiveness of Xpert MTB/RIF and the Line Probe Assay Tests for the Rapid Detection of Drug-Resistant Tuberculosis in the Central African Republic.” PLOS Global Public Health, 2023.
Ankur Kumar, A. Singh, Vivek Gaur, A. Mishra, Anita Mehta, and Raj Kishore Singh. “Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.” International Journal of Mycobacteriology, 2025.
B. Phetsuksiri, W. Klayut, J. Rudeeaneksin, S. Srisungngam, S. Bunchoo, Sarawut Toonkomdang, T. Wongchai, C. Nakajima, and Yasuhiko Suzuki. “The Performance of an in-House Loop-Mediated Isothermal Amplification for the Rapid Detection of Mycobacterium Tuberculosis in Sputum Samples in Comparison with Xpert MTB/RIF, Microscopy and Culture.” Revista Do Instituto de Medicina Tropical de São Paulo, 2020.
B. Reeve, G. Ndlangalavu, H. Mishra, Z. Palmer, H. Tshivhula, L. Rockman, S. Naidoo, et al. “Point-of-Care C-Reactive Protein and Xpert MTB/RIF Ultra for Tuberculosis Screening and Diagnosis in Unselected Antiretroviral Therapy Initiators: A Prospective Diagnostic Accuracy Study.” medRxiv, 2023.
B. Saavedra, E. Mambuque, D. Nguenha, N. Gomes, S. Munguambe, J. García, S. Izco, et al. “Diagnostic Performance of Xpert MTB/RIF Ultra for Tuberculosis Diagnosis in the Context of Passive and Active Case Finding Strategies in Rural Mozambique.” Social Science Research Network, 2021.
B. Schmidt, H. Geldenhuys, M. Tameris, A. Luabeya, H. Mulenga, E. Bunyasi, T. Scriba, and M. Hatherill. “Impact of Xpert MTB/RIF Rollout on Management of Tuberculosis in a South African Community.” South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde, 2017.
C. Boehme, M. Nicol, P. Nabeta, J. Michael, E. Gotuzzo, Rasim Tahirli, Maria Tarcela Gler, et al. “Feasibility, Diagnostic Accuracy, and Effectiveness of Decentralised Use of the Xpert MTB/RIF Test for Diagnosis of Tuberculosis and Multidrug Resistance: A Multicentre Implementation Study.” The Lancet, 2011.
C. Boehme, P. Nabeta, D. Hillemann, M. Nicol, S. Shenai, F. Krapp, J. Allen, et al. “Rapid Molecular Detection of Tuberculosis and Rifampin Resistance.” New England Journal of Medicine, 2010.
C. H. Ding, Z. Ismail, A. Sulong, A. Wahab, B. Gan, S. Mustakim, and H. Ahmad. “The Reliability of a Rapid Molecular Detection Method in Determining the Prevalence of Rifampicin-Resistant Mycobacterium Tuberculosis in an Urban District Health Facility in Malaysia.” The Malaysian Journal of Pathology, 2020.
C. Habeenzu, C. Nakajima, E. Solo, Precious Bwalya, K. Kajino, M. Miller, Youichi Kurosawa, et al. “Evaluation of in-House Loop-Mediated Isothermal Amplification for Tuberculosis Diagnosis Compared with Xpert MTB/RIF.” Journal of Infection in Developing Countries, 2017.
C. Hanrahan, Katerina Selibas, C. Deery, H. Dansey, K. Clouse, J. Bassett, L. Scott, W. Stevens, I. Sanne, and A. Van Rie. “Time to Treatment and Patient Outcomes Among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa.” PLoS ONE, 2013.
C. Modongo, N. Zetola, M. Pandori, and J. Klausner. “Has the Answer to Diagnosing TB in Resource-Limited Settings Been Found?” MLO: Medical Laboratory Observer, 2011.
C. Nikam, Manjula Jagannath, M. Narayanan, Vinaya Ramanabhiraman, M. Kazi, A. Shetty, and C. Rodrigues. “Rapid Diagnosis of Mycobacterium Tuberculosis with Truenat MTB: A Near-Care Approach.” PLoS ONE, 2013.
C. Vuchas, Pride Teyim, Beh Frankline Dang, Angela Neh, Liliane Keugni, Mercy Che, Pantalius Nji Che, et al. “Implementation of Large-Scale Pooled Testing to Increase Rapid Molecular Diagnostic Test Coverage for Tuberculosis: A Retrospective Evaluation.” Scientific Reports, 2023.
D. Nair, Pooranaganga D Navneethapandian, J. Tripathy, A. Harries, J. Klinton, Basilea Watson, G. Sivaramakrishnan, et al. “Impact of Rapid Molecular Diagnostic Tests on Time to Treatment Initiation and Outcomes in Patients with Multidrug-Resistant Tuberculosis, Tamil Nadu, India.” Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016.
D. Osório, I. Munyangaju, A. Muhiwa, Edy Nacarapa, A. Nhangave, and J. Ramos. “Lipoarabinomannan Antigen Assay (TB-LAM) for Diagnosing Pulmonary Tuberculosis in Children with Severe Acute Malnutrition in Mozambique.” Journal of Tropical Pediatrics, 2020.
D. V. van Hoving, G. Meintjes, G. Maartens, and A. Kengne. “A Multi-Parameter Diagnostic Clinical Decision Tree for the Rapid Diagnosis of Tuberculosis in HIV-Positive Patients Presenting to an Emergency Centre.” Wellcome Open Research, 2020.
D. Wilson, P. Cudahy, and P. Drain. “Urine and Sputum Tuberculosis Tests: Defining the Trade-Offs in Endemic HIV and Tuberculosis Settings.” Lancet Global Health, 2023.
Dana Hassneiah, Aliya Moreira, Bada Yang, Mathias Weis Damkjaer, Laura Olbrich, Stephanie Bjerrum, Maunank Shah, and R. Nathavitharana. “P-770. Impact of Parallel Use of Low-Complexity Automated Nucleic Acid Amplification Tests and Urine Lateral Flow Lipoarabinomannan Assays to Detect Tuberculosis in People Living with HIV.” Open Forum Infectious Diseases, 2025.
Dwi Robbiardy Eksa, Gatot Sudiro Hendarto, Fransisca TY Sinaga, Pad Dilangga, M. J. D. Herdato, Andreas Infianto, Diyan Ekawati, Achmad Gozali, and Adhari Ajipurnomo. “Comparative Diagnostic Accuracy of LF-LAM TB Antigen and Xpert MTB/RIF in Pulmonary Tuberculosis Among Underweight Patients.” Jurnal Respirologi Indonesia, 2025.
E. Ardizzoni, E. Fajardo, P. Saranchuk, Martina Casenghi, A. Page, F. Varaine, C. Kosack, and P. Hepple. “Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.” PLoS ONE, 2015.
E. Walters, M. M. van der Zalm, M. Palmer, Corné Bosch, A. Demers, H. Draper, P. Goussard, et al. “Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease.” The Pediatric Infectious Disease Journal, 2017.
Ehsan Aryan, M. Makvandi, A. Farajzadeh, K. Huygen, Amirhooshang Alvandi, M. Gouya, A. Sadrizadeh, and M. Romano. “Clinical Value of IS6110-Based Loop-Mediated Isothermal Amplification for Detection of Mycobacterium Tuberculosis Complex in Respiratory Specimens.” Journal of Infection, 2013.
Eunita D. A. Ochola, and M. Mweu. “Performance of Three Diagnostic Tests for Tuberculosis Among Human Immunodeficiency Virus (HIV) Patients Presenting to a Health Facility in an Informal Urban Settlement in Nairobi, Kenya.” PLoS ONE, 2024.
Evrevin Marine, Hermet Loïc, Guillet-Caruba Christelle, Nivose Pierre-Louis, Sordoillet Vallier, Mellon Guillaume, Dulioust Anne, and Doucet-Populaire Florence. “Improving Tuberculosis Management in Prisons: Impact of a Rapid Molecular Point-of-Care Test.” Journal of Infection, 2020.
F. Bwanga, M. Haile, M. Joloba, E. Ochom, and S. Hoffner. “Direct Nitrate Reductase Assay Versus Microscopic Observation Drug Susceptibility Test for Rapid Detection of MDR-TB in Uganda.” PLoS ONE, 2011.
F. Haraka, Mwaka A. Kakolwa, S. Schumacher, R. Nathavitharana, C. Denkinger, S. Gagneux, K. Reither, and A. Ross. “Impact of the Diagnostic Test Xpert MTB/RIF on Patient Outcomes for Tuberculosis.” Cochrane Database of Systematic Reviews, 2021.
F. Saluzzo, F. Masood, V. Batignani, F. di Marco, U. Majeed, A. Ghazal, D. M. Cirillo, and S. Tahseen. “TB Drug Susceptibility Testing in High Fluoroquinolone Resistance Settings.” IJTLD Open, 2024.
Faridath Massou, Awa Ba, K. Bah, C. Vuchas, Fadeyi Muse, M. Kaswa, C. Semuto, et al. “OA-484 Improving Rapid Detection of 2nd Line Drug Resistance in Mycobacterium Tuberculosis with Xpert MTB/XDR and MolBio 2nd Line.” Abstracts of Oral Presentations, 2023.
Fatima Zahra, A. Ikram, G. Zaman, L. Satti, F. Lalani, and Mariam Khan. “Diagnosis of Pulmonary Tuberculosis in Resource Limited Setting of Rawalpindi.” Open Microbiology Journal, 2018.
G. Alvarez-Uria, J. M. Azcona, Manoranjan Midde, P. K. Naik, Srinivasulu Reddy, and Raghuprakash Reddy. “Rapid Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in HIV-Infected Patients. Comparison of LED Fluorescent Microscopy and the GeneXpert MTB/RIF Assay in a District Hospital in India.” Tuberculosis Research and Treatment, 2012.
G. Calligaro, L. Zijenah, J. Peter, G. Theron, V. Buser, R. McNerney, Wilbert Bara, et al. “Effect of New Tuberculosis Diagnostic Technologies on Community-Based Intensified Case Finding: A Multicentre Randomised Controlled Trial.” Lancet. Infectious Diseases (Print), 2017.
G. Carriquiry, L. Otero, E. González-Lagos, C. Zamudio, E. Sánchez, P. Nabeta, M. Campos, J. Echevarría, C. Seas, and E. Gotuzzo. “A Diagnostic Accuracy Study of Xpert®MTB/RIF in HIV-Positive Patients with High Clinical Suspicion of Pulmonary Tuberculosis in Lima, Peru.” PLoS ONE, 2012.
G. Churchyard, W. Stevens, L. D. Mametja, K. McCarthy, V. Chihota, M. Nicol, L. K. Erasmus, et al. “Xpert MTB/RIF Versus Sputum Microscopy as the Initial Diagnostic Test for Tuberculosis: A Cluster-Randomised Trial Embedded in South African Roll-Out of Xpert MTB/RIF.” Lancet Global Health, 2015.
G. M. Kassa, M. Merid, A. G. Muluneh, and H. F. Wolde. “Comparing the Impact of Genotypic Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes Among Drug-Resistant Tuberculosis Patients in Amhara Region, Ethiopia.” PLoS ONE, 2021.
G. Theron, A. Pooran, J. Peter, R. V. van Zyl-Smit, H. Kumar Mishra, R. Meldau, G. Calligaro, et al. “Do Adjunct Tuberculosis Tests, When Combined with Xpert MTB/RIF, Improve Accuracy and the Cost of Diagnosis in a Resource-Poor Setting?” European Respiratory Journal, 2011.
G. Theron, J. Peter, R. V. van Zyl-Smit, H. Mishra, E. Streicher, S. Murray, R. Dawson, et al. “Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting.” American Journal of Respiratory and Critical Care Medicine, 2011.
G. Theron, L. Zijenah, D. Chanda, P. Clowes, and for the Lancet Neonatal Survival Steering Team. “Feasibility, Accuracy, and Clinical Effect of Point-of-Care Xpert MTB/RIF Testing for Tuberculosis in Primary-Care Settings in Africa: A Multicentre, Randomised, Controlled Trial.” The Lancet, 2014.
Gangarathna Krishna, C. Valsan, and S. K. A. “LOOP MEDIATED ISOTHERMAL AMPLIFICATION FOR THE RAPID DIAGNOSIS OF PULMONARY TUBERCULOSIS.” Journal of Evolution of Medical and Dental Sciences, 2019.
Gayathri Ramasubban, J. S. Michael, Richa Gupta, Kavyasri Channamaneni, Dhanabagyam Krishnan, Dev Chandran, Sven Hoffner, and Pavan Asalapuram. “Novel Diagnostic Test for the Detection of Mycobacterium Tuberculosis and Its Resistance to Rifampicin, Isoniazid, and Fluoroquinolones Directly in Sputum Samples.” Frontiers in Tuberculosis, 2025.
H. Albert, A. Heydenrych, R. Brookes, R. Mole, B. Harley, E. Subotsky, R. Henry, and V. Azevedo. “Performance of a Rapid Phage-Based Test, FASTPlaqueTB, to Diagnose Pulmonary Tuberculosis from Sputum Specimens in South Africa.” The International Journal of Tuberculosis and Lung Disease, 2002.
H. Zar, L. Workman, W. Isaacs, K. Dheda, W. Zemanay, and M. Nicol. “Rapid Diagnosis of Pulmonary Tuberculosis in African Children in a Primary Care Setting by Use of Xpert MTB/RIF on Respiratory Specimens: A Prospective Study.” Lancet Global Health, 2013.
Hsiang-Wei Lu, R. Sakamuri, P. Kumar, Tanya M. Ferguson, R. Doebler, Keith Herrington, Ryan Talbot, et al. “Integrated Nucleic Acid Testing System to Enable TB Diagnosis in Peripheral Settings.” Lab on a Chip, 2020.
I. Mutingwende, U. Vermeulen, Faans Steyn, H. Viljoen, and A. Grobler. “Development and Evaluation of a Rapid Multiplex-PCR Based System for Mycobacterium Tuberculosis Diagnosis Using Sputum Samples.” Journal of Microbiological Methods, 2015.
I. Ullah, A. Javaid, H. Masud, Mazhar Ali, A. Basit, W. Ahmad, F. Younis, et al. “Rapid Detection of Mycobacterium Tuberculosis and Rifampicin Resistance in Extrapulmonary Tuberculosis and Sputum Smear‐negative Pulmonary Suspects Using Xpert MTB/RIF.” Journal of Medical Microbiology, 2017.
Isabel Cuella-Martin, F. Hakizayezu, Ayman Ahmed, D. Runyambo, H. Niyompano, J. Keysers, W. D. de Rijk, et al. “Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings.” Clinical Infectious Diseases, 2025.
J. Cavanaugh, S. Modi, S. Musau, K. McCarthy, H. Alexander, B. Burmen, C. Heilig, R. Shiraishi, and K. Cain. “Comparative Yield of Different Diagnostic Tests for Tuberculosis Among People Living with HIV in Western Kenya.” PLoS ONE, 2016.
J. L. Davis, A. Cattamanchi, L. Cuevas, P. Hopewell, and K. Steingart. “Diagnostic Accuracy of Same-Day Microscopy Versus Standard Microscopy for Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis.” Lancet. Infectious Diseases (Print), 2013.
J. Malacarne, A. Heirich, E. Cunha, I. Kolte, R. Souza-Santos, and P. C. Basta. “Performance of Diagnostic Tests for Pulmonary Tuberculosis in Indigenous Populations in Brazil: The Contribution of Rapid Molecular Testing.” Jornal Brasileiro de Pneumologia, 2019.
J. Thoulass, E. Katabira, S. Kunustor, J. Walley, and M. Evans. “P2-484 Diagnosis of Smear Negative Pulmonary Tuberculosis in Low and Middle Income Countries.” Journal of Epidemiology and Community Health, 2011.
J. Zarocostas. “New Molecular Test Can Diagnose Tuberculosis in Less Than Two Hours.” British Medical Journal, 2010.
Jacob Creswell, Bishwa Rai, R. Wali, Santat Sudrungrot, Lal Mani Adhikari, R. Pant, S. Pyakurel, D. Uranw, and A. Codlin. “Introducing New Tuberculosis Diagnostics: The Impact of Xpert(®) MTB/RIF Testing on Case Notifications in Nepal.” The International Journal of Tuberculosis and Lung Disease, 2015.
Jae Hyoung Lee, Tushar Garg, Jungsil Lee, S. McGrath, L. Rosman, S. Schumacher, A. Benedetti, et al. “Impact of Molecular Diagnostic Tests on Diagnostic and Treatment Delays in Tuberculosis: A Systematic Review and Meta-Analysis.” BMC Infectious Diseases, 2022.
Jing Peng, Juan Song, Feng Wang, P. Zuo, Yanjun Lu, Weiyong Liu, L. Tian, et al. “Harnessing Big Data to Optimize an Algorithm for Rapid Diagnosis of Pulmonary Tuberculosis in a Real-World Setting.” Frontiers in Cellular and Infection Microbiology, 2021.
Juan Carlos Garberi, Gabriel Estryk, Richard Chiara, Patricia Callisperis, Patricia Loza, Luis Scigliano, Sandra Andrea Casevecchie, et al. “Diagnostic Accuracy of the Novel and Biosafe Molecular Assay Orange G3 TBC Compared to GeneXpert for Tuberculosis Diagnosis in Resource-Limited Settings.” Therapeutic Advances in Infectious Disease, 2025.
K. Choun, T. Decroo, T. E. Mao, N. Lorent, L. Gerstel, J. Creswell, A. Codlin, L. Lynen, and S. Thai. “Performance of Algorithms for Tuberculosis Active Case Finding in Underserved High-Prevalence Settings in Cambodia: A Cross-Sectional Study.” Global Health Action, 2019.
K. Dheda, R. V. van Zyl-Smit, R. Meldau, S. Meldau, G. Symons, H. Khalfey, N. Govender, et al. “Quantitative Lung T Cell Responses Aid the Rapid Diagnosis of Pulmonary Tuberculosis.” Thorax, 2009.
K. Kawkitinarong, G. Suwanpimolkul, P. Kateruttanakul, W. Manosuthi, S. Ubolyam, J. Sophonphan, A. Avihingsanon, and K. Ruxrungtham. “Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.” Clinical Infectious Diseases, 2017.
K. Leung, G. Siu, Kingsley King-Gee Tam, P. Ho, Samson S. Y. Wong, Eunice Leung, Shiyu Yu, Oliver Chiu Kit Ma, and W. Yam. “Diagnostic Evaluation of an in-House Developed Single-Tube, Duplex, Nested IS6110 Real-Time PCR Assay for Rapid Pulmonary Tuberculosis Diagnosis.” Tuberculosis, 2018.
K. Myo, M. Zaw, T. L. Swe, Y. Y. Kyaw, T. Thwin, T. Myo, K. Aye, and A. Myint. “Evaluation of Xpert® MTB/RIF Assay as a Diagnostic Test for Pulmonary Tuberculosis in Children in Myanmar.” The International Journal of Tuberculosis and Lung Disease, 2018.
K. Reither, Christina Manyama, P. Clowes, A. Rachow, D. Mapamba, A. Steiner, A. Ross, et al. “Xpert MTB/RIF Assay for Diagnosis of Pulmonary Tuberculosis in Children: A Prospective, Multi-Centre Evaluation.” Journal of Infection, 2015.
K. Sachdeva, N. Raizada, A. Sreenivas, A. H. V. Hoog, S. Hof, P. Dewan, R. Thakur, et al. “Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.” PLoS ONE, 2015.
K. Sharma, Megha Sharma, Lokesh Chaudhary, M. Modi, M. Goyal, N. Sharma, Aman Sharma, et al. “Comparative Evaluation of Xpert MTB/RIF Assay with Multiplex Polymerase Chain Reaction for the Diagnosis of Tuberculous Meningitis.” Tuberculosis, 2018.
K. Steingart. “Xpert MTB/RIF Test for Detection of Pulmonary Tuberculosis and Rifampicin Resistance,” 2013.
K. Steingart, Hojoon Sohn, Ian Schiller, Lorie A. Kloda, C. Boehme, M. Pai, and N. Dendukuri. “Xpert® Mtb/Rif Assay for Pulmonary Tuberculosis and Rifampicin Resistance in Adults.” Cochrane Database of Systematic Reviews, 2013.
K. Steingart, Ian Schiller, David J Horne, Madhukar Pai, C. Boehme, and N. Dendukuri. “Xpert® MTB/RIF Assay for Pulmonary Tuberculosis and Rifampicin Resistance in Adults.” Cochrane Database of Systematic Reviews, 2014.
K. Suryana, Hamong Suharsono, and Ida Bagus Ngurah Rai. “THE DIAGNOSTIC VALUE OF CONVENTIONAL TUBERCULOSIS DIAGNOSTIC PROCEDURE COMPARED WITH GENE X-PERT MTB/RIF: A CROSS-SECTIONAL STUDY.” Asian Journal of Pharmaceutical and Clinical Research, 2020.
L. Inbaraj, Jefferson Daniel, Mukesh Kumar Sathya Narayanan, Vignes Anand Srinivasalu, Adhin Bhaskar, K. Scandrett, Priya Rajendran, et al. “Truenat MTB Assays for Pulmonary Tuberculosis and Rifampicin Resistance in Adults and Adolescents.” Cochrane Database of Systematic Reviews, 2025.
L. Inbaraj, Mukesh Kumar Sathya Narayanan, Jefferson Daniel, Vignes Anand Srinivasalu, Adhin Bhaskar, Bella Devaleenal Daniel, Tephilla Epsibha, et al. “Low‐complexity Manual Nucleic Acid Amplification Tests for Pulmonary Tuberculosis in Children.” Cochrane Database of Systematic Reviews, 2025.
L. Kivihya-Ndugga, M. Cleeff, W. Githui, L. Nganga, D. Kibuga, J. Odhiambo, and P. Klatser. “A Comprehensive Comparison of Ziehl-Neelsen and Fluorescence Microscopy for the Diagnosis of Tuberculosis in a Resource-Poor Urban Setting.” The International Journal of Tuberculosis and Lung Disease, 2003.
L. Martinez, and J. Andrews. “Improving Tuberculosis Case Finding in Persons Living with Advanced HIV Through New Diagnostic Algorithms.” American Journal of Respiratory and Critical Care Medicine, 2019.
L. Nakiyingi, Prossy Nakanwagi, J. Briggs, Tifu Agaba, F. Mubiru, M. Mugenyi, W. Ssengooba, M. Joloba, and Y. Manabe. “Performance of Loop-Mediated Isothermal Amplification Assay in the Diagnosis of Pulmonary Tuberculosis in a High Prevalence TB/HIV Rural Setting in Uganda.” BMC Infectious Diseases, 2018.
L. Scott, K. McCarthy, N. Gous, M. Nduna, A. Van Rie, I. Sanne, W. Venter, A. Dusé, and W. Stevens. “Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study.” PLoS Medicine, 2011.
Ligamena N. Kakoma, Munyaradzi Mukesi, and S. Moyo. “Effectiveness of GeneXpert Technology in the Diagnosis of Smear-Negative Pulmonary Mycobacterium Tuberculosis in HIV Positive Patients in Namibia,” 2016.
M. Alao, O. O., Ogunbosi Oluwatosin B., Joseph Adejoke A., Akinboro Adeolu O., and I. R. “Nucleic Acid–Based Rapid Detection of Tuberculosis and Rifampicin Resistance in a Resource-Limited Setting,” 2021.
M. Barnard, H. Albert, G. Coetzee, R. O'brien, and M. Bosman. “Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa.” American Journal of Respiratory and Critical Care Medicine, 2008.
M. Cleeff, L. Kivihya-Ndugga, W. Githui, L. Nganga, D. Kibuga, J. Odhiambo, and P. Klatser. “Cost-Effectiveness of Polymerase Chain Reaction Versus Ziehl-Neelsen Smear Microscopy for Diagnosis of Tuberculosis in Kenya.” The International Journal of Tuberculosis and Lung Disease, 2005.
M. Kasaro, B. Muluka, Kaunda Kaunda, J. Morse, A. Westfall, N. Kapata, A. Kruuner, G. Henostroza, and S. Reid. “PERFORMANCE OF XPERT MTB/RIF AND DETERMINE LAM IN HIV-INFECTED ADULTS IN PERI-URBAN SITES IN ZAMBIA (CDC OP-X STUDY).” BMJ Global Health, 2017.
M. Kasaro, O. Chilyabanyama, N. Shah, B. Muluka, N. Kapata, A. Krüüner, I. Mwaba, et al. “Performance of Xpert® MTB/RIF and Determine™ TB-LAM Ag in HIV-Infected Adults in Peri-Urban Sites in Zambia.” Public Health Action, 2020.
M. Muyoyeta, M. Moyo, Nkatya Kasese, Mapopa Ndhlovu, Deborah Milimo, W. Mwanza, N. Kapata, A. Schaap, Peter Godfrey Faussett, and H. Ayles. “Correction: Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings.” PLoS ONE, 2015.
———. “Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings.” PLoS ONE, 2015.
M. Shah, W. Ssengooba, D. Armstrong, L. Nakiyingi, Molly Holshouser, J. Ellner, M. Joloba, Y. Manabe, and S. Dorman. “Comparative Performance of Urinary Lipoarabinomannan Assays and Xpert MTB/RIF in HIV-Infected Individuals.” AIDS (London), 2014.
M. Singh, G. Sethi, M. Mantan, A. Khanna, and M. Hanif. “Xpert(®) MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in Children.” The International Journal of Tuberculosis and Lung Disease, 2016.
Madhumathi Jayaprakasam, J. S. Michael, P. Jain, Shaoli Basu, K. Ajbani, Siva Kumar Shanmugam, M. Ninan, et al. “Diagnostic Accuracy of Real-Time PCR Assay ‘Quantiplus® MTB FAST’ for Detection of Adult Pulmonary Tuberculosis (PTB): A Multi-Centric Study.” The Indian Journal of Medical Research, 2025.
Mansuri M.Z, Jain S., S. M., J. A., and Agrawat J.C. “A STUDY OF IMPACT OF CBNAAT IN THE DIAGNOSIS OF TUBERCULOSIS AT A RURAL BASED TERTIARY CARE TEACHING CENTRE IN INDIA.” International Journal of Advanced Research, 2025.
N. Javanshir, D. S. Shah, D. E. Jennings, Juraj Ivanyi, and Heather Milburn. “P165 TB-ST Rapid Test for Tuberculosis Diagnosis in a Resource Poor Setting: Are Cases of Tuberculosis Going Undiagnosed?” Thorax, 2010.
N. Lorent, C. Kong, R. Pe, Tharin Kim, S. Sok, S. Thai, R. Leen, and L. Lut. “Implementation of Rapid Drug-Susceptibility Testing for Patients at High Risk of Multidrug-Resistant Tuberculosis in Cambodia,” 2013.
N. Lorent, C. Kong, T. Kim, S. Sam, S. Thai, R. Colebunders, L. Rigouts, and L. Lynen. “Systematic Screening for Drug-Resistant Tuberculosis with Xpert(®) MTB/RIF in a Referral Hospital in Cambodia.” The International Journal of Tuberculosis and Lung Disease, 2015.
N. Raizada, K. Sachdeva, A. Sreenivas, Shubhangi Kulsange, Radhey Shyam Gupta, R. Thakur, P. Dewan, C. Boehme, and C. N. Paramsivan. “Catching the Missing Million: Experiences in Enhancing TB & DR-TB Detection by Providing Upfront Xpert MTB/RIF Testing for People Living with HIV in India.” PLoS ONE, 2015.
N. Raizada, K. Sachdeva, S. Nair, Shubhangi Kulsange, Radhey Shyam Gupta, R. Thakur, M. Parmar, et al. “Enhancing TB Case Detection: Experience in Offering Upfront Xpert MTB/RIF Testing to Pediatric Presumptive TB and DR TB Cases for Early Rapid Diagnosis of Drug Sensitive and Drug Resistant TB.” PLoS ONE, 2014.
N. Raizada, S. Khaparde, V. S. Salhotra, R. Rao, A. Kalra, S. Swaminathan, A. Khanna, et al. “Accelerating Access to Quality TB Care for Pediatric TB Cases Through Better Diagnostic Strategy in Four Major Cities of India.” PLoS ONE, 2018.
N. Shah, P. Moodley, Palav Babaria, S. Moodley, M. Ramtahal, J. Richardson, S. Heysell, et al. “Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay.” American Journal of Respiratory and Critical Care Medicine, 2011.
N. Tukvadze, R. Kempker, I. Kalandadze, E. Kurbatova, M. Leonard, R. Apsindzelashvili, N. Bablishvili, M. Kipiani, and H. Blumberg. “Use of a Molecular Diagnostic Test in AFB Smear Positive Tuberculosis Suspects Greatly Reduces Time to Detection of Multidrug Resistant Tuberculosis.” PLoS ONE, 2012.
Nathakorn Pongpeeradech, Yuthichai Kasetchareo, C. Chuchottaworn, S. Lawpoolsri, U. Silachamroon, and J. Kaewkungwal. “Evaluation of the Use of GeneXpert MTB/RIF in a Zone with High Burden of Tuberculosis in Thailand.” PLoS ONE, 2022.
Nirajan Bhusal, Sunaina Shrestha, N. Pote, and E. Alocilja. “Nanoparticle-Based Biosensing of Tuberculosis, an Affordable and Practical Alternative to Current Methods.” Biosensors, 2018.
Noormohamad Mansoori, Fateme Arabmofrad, and Bagher Pahlavanzadeh. “Evaluation of the Xpert MTB/RIF Test Accuracy for Rapid Diagnosis of Pulmonary Tuberculosis in a Tuberculosis Endemic Area,” 2021.
P. Ghosh, S. Anwar, Martin Siegel, J. B. Okuni, Manfred Weidmann, Nishad Tasnim Mithila, Kevin Cassar, et al. “Assessing the Performance of a Point-of-Need Diagnostic Algorithm in Rapid Detection of Peripheral Lymph Node Tuberculosis (Mobile-TB-Lab): A Diagnostic Evaluation Study Protocol.” BMJ Open, 2025.
P. Orikiriza. “Improving Diagnosis of Childhood Tuberculosis in a High TB-HIV Prevalent Setting,” 2019.
P. Shete, K. Farr, L. Strnad, C. Gray, and A. Cattamanchi. “Diagnostic Accuracy of TB-LAMP for Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis.” BMC Infectious Diseases, 2019.
P. Shete, T. Nalugwa, K. Farr, Christopher Ojok, M. Nantale, P. Howlett, P. Haguma, et al. “Feasibility of a Streamlined Tuberculosis Diagnosis and Treatment Initiation Strategy.” The International Journal of Tuberculosis and Lung Disease, 2017.
Prakash Shrestha, H. Khanal, P. Dahal, and P. Dongol. “Programmatic Impact of Implementing GeneXpert MTB/ RIF Assay for the Detection of Mycobacterium Tuberculosis in Respiratory Specimens from Pulmonary Tuberculosis Suspected Patients in Resource Limited Laboratory Settings of Eastern Nepal.” Open Microbiology Journal, 2018.
R. J. Bowerman. “Rapid Detection of Tuberculosis in Remote Alaska.” International Journal of Circumpolar Health, 2020.
R. Lessells. “Impact of the Xpert MTB/RIF Tuberculosis Diagnosticsystem in Individuals at High Risk of Mortality in ruralSouth Africa,” 2015.
R. McNerney, and Alimuddin Zumla. “Impact of the Xpert MTB/RIF Diagnostic Test for Tuberculosis in Countries with a High Burden of Disease.” Current Opinion in Pulmonary Medicine, 2015.
R. Nathavitharana. “Stamping Out Tuberculosis: The Importance of Diagnostic Innovation and Effective Implementation.” Annals of the American Thoracic Society, 2019.
R. Philipsen, C. I. Sánchez, P. Maduskar, Jaime Melendez, Liesbeth Peters-Bax, J. Peter, R. Dawson, G. Theron, K. Dheda, and B. Ginneken. “Automated Chest-Radiography as a Triage for Xpert Testing in Resource-Constrained Settings: A Prospective Study of Diagnostic Accuracy and Costs.” Scientific Reports, 2015.
R. Rakotoarivelo, J. Ambrosioni, V. Rasolofo, M. Raberahona, N. Rakotosamimanana, R. L. Andrianasolo, R. Ramanampamonjy, et al. “Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis in Madagascar.” International Journal of Infectious Diseases, 2018.
R. Yadav, N. Sharma, R. Khaneja, P. Agarwal, A. Kanga, D. Behera, and S. Sethi. “Evaluation of the TB-LAMP Assay for the Rapid Diagnosis of Pulmonary Tuberculosis in Northern India.” The International Journal of Tuberculosis and Lung Disease, 2017.
S. Auld, B. Moore, Ryan P Kyle, B. Eng, K. Nong, E. Pevzner, K. K. Eam, M. T. Eang, and W. P. Killam. “Mixed Impact of Xpert(®) MTB/RIF on Tuberculosis Diagnosis in Cambodia.” Public Health Action, 2016.
S. Hermans, J. Caldwell, R. Kaplan, F. Cobelens, and R. Wood. “The Impact of the Roll-Out of Rapid Molecular Diagnostic Testing for Tuberculosis on Empirical Treatment in Cape Town, South Africa.” Bulletin of the World Health Organization, 2017.
S. Jha, N. Ismail, D. Clark, James J. Lewis, S. Omar, A. Dreyer, V. Chihota, G. Churchyard, and D. Dowdy. “Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis.” PLoS ONE, 2016.
S. Kaswabuli, E. Musisi, P. Byanyima, A. Sessolo, I. Sanyu, J. Zawedde, W. Worodria, Laurence Huang, Alfred Okeng, and F. Bwanga. “Accuracy of GenoQuick MTB Test in Detection of Mycobacterium Tuberculosis in Sputum from TB Presumptive Patients in Uganda.” SAGE Open Medicine, 2022.
S. LaCourse, L. Cranmer, Daniel Matemo, J. Kinuthia, B. Richardson, G. John-Stewart, and D. Horne. “Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic Tests.” Journal of Acquired Immune Deficiency Syndromes, 2016.
S. Lawn, A. Kerkhoff, M. Vogt, and R. Wood. “Diagnostic Accuracy of a Low-Cost, Urine Antigen, Point-of-Care Screening Assay for HIV-Associated Pulmonary Tuberculosis Before Antiretroviral Therapy: A Descriptive Study.” Lancet. Infectious Diseases (Print), 2012.
S. Swaminathan, and VV Banu Rekha. “Antigen Detection as a Point-of-Care Test for TB: The Case of Lipoarabinomannan.” Future Microbiology, 2012.
S. V. van Kampen, A. Tursynbayeva, A. Koptleuova, Z. Murzakhmetova, Lyazzat Bigalieva, Moldir Aubakirova, S. Pak, and S. van den Hof. “Correction: Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.” PLoS ONE, 2015.
S. V. van Kampen, A. Tursynbayeva, A. Koptleuova, Zauresh Murzabekova, Lyazzat Bigalieva, Moldir Aubakirova, S. Pak, and S. van den Hof. “Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.” PLoS ONE, 2015.
S. V. van Kampen, N. Susanto, S. Simon, Shinta D. Astiti, Roni Chandra, Erlina Burhan, M. Farid, K. Chittenden, D. Mustikawati, and B. Alisjahbana. “Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.” PLoS ONE, 2015.
S. Walmsley. “ACP Journal Club: Review: Xpert MTB/RIF Assay Detects Extrapulmonary TB in Lymph Nodes and CSF, but Not Pleural Fluid.” Annals of Internal Medicine, 2015.
S. Walusimbi, F. Bwanga, A. Costa, M. Haile, S. Hoffner, and M. Joloba. “Evaluation of the Xpert® MTB/Rif Test, Microscopic Observation Drug Susceptibility Test and Nitrate Reductase Assay, for Rapid and Accurate Diagnosis of Smear-Negative Tuberculosis in HIV Patients.” International Journal of Mycobacteriology, 2013.
Sabina Mugusi, Jacob Lema, Peter Ponsian, Doreen Kamori, Happiness Kimambo, Paul Masanja, Avitus Anthony, Mwemezi Ngemera, and Amos Kahwa. “Diagnostic Accuracy of Sputum Smear Microscopy Compared with Culture in Patients with Tuberculosis Confirmed by Xpert Mycobacterium Tuberculosis/Rifampicin Assay in Tanzania: A Cross-Sectional Study.” Journal of International Medical Research, 2025.
Sekai Chenai Mathabire Rucker, L. Cossa, R. Harrison, J. Mpunga, S. Lobo, Patrick Kisaka Kimupelenge, Felix Mandar Kol'Ampwe, et al. “Feasibility of Using Determine TB-LAM to Diagnose Tuberculosis in HIV-Positive Patients in Programmatic Conditions: A Multisite Study.” Global Health Action, 2019.
Sharon Kasa Tom, H. Welch, Cornelia Kilalang, N. Tefuarani, J. Vince, E. Lavu, Karen C. Johnson, R. Magaye, and T. Duke. “Evaluation of Xpert MTB/RIF Assay in Children with Presumed Pulmonary Tuberculosis in Papua New Guinea.” Paediatrics and International Child Health, 2018.
Shimba Henerico, Richard V. Makapa, Bernard C. Okamo, Benson R. Kidenya, Geoffrey Japhet, Lisa Gerwing-Adima, and C. Kasang. “Pooled Sputum for Xpert MTB/RIF Testing: A Cost Effectiveness Diagnostic Tool in Mwanza, Tanzania,” 2021.
Sonam Dolker, R. Verma, C. Prakash, and Ashabree Shamal. “Application of Loop Mediated Isothermal Amplification (LAMP) Assay as an Alternative Diagnostic Test for Rapid Tuberculosis Diagnosis in Limited Resource Setting.” Indian Journal of Animal Sciences, 2012.
Sri Kartika Sari, and Aryati Aryati. “NILAI DIAGNOSTIK ANTIGEN TB DENGAN RAPID TEST DEVICE (TB AG) UNTUK TUBERKULOSIS PARU,” 2016.
Surabhi Lavania, Ritu Das, A. Dhiman, V. Myneedu, A. Verma, Nagendra Singh, T. K. Sharma, and J. Tyagi. “Aptamer-Based TB Antigen Tests for the Rapid Diagnosis of Pulmonary Tuberculosis: Potential Utility in Screening for Tuberculosis.” ACS Infectious Diseases, 2018.
Swati B Gajbhiye, M. Madkey, and D Sharad Gedam. “Pattern of Tuberculosis Among Tribal Population of Central India with Special Reference to Cartridge Based Nucleic Acid Amplification Test as Diagnostic Tool: A Descriptive Study at Tertiary Care Hospital.” International Journal of Research in Medical Sciences, 2019.
T. Balcha, E. Sturegård, N. Winqvist, S. Skogmar, Anton Reepalu, Z. H. Jemal, Gudeta Tibesso, T. Schön, and P. Björkman. “Intensified Tuberculosis Case-Finding in HIV-Positive Adults Managed at Ethiopian Health Centers: Diagnostic Yield of Xpert MTB/RIF Compared with Smear Microscopy and Liquid Culture.” PLoS ONE, 2014.
T. Malaquias, Ana Paula Santos, E. Costa, F. Mello, and A. Kritski. “Comparative Evaluation of the Rapid Diagnostic Assays for Detecting Tuberculosis (TB) in a Reference Center for Drug Resistant TB in Brazil,” 2020.
T. Perumal, S. Jaumdally, A. Esmail, Mohammed Limbada, Ashley Chizema, Isabel Timana, A. Scott, et al. “PA-139 Impact of Molecular Diagnostic Tools for Community-Based Active Case-Finding: A Multicentre Randomised Controlled Trial.” Abstracts of Poster and e-Poster Presentations, 2023.
T. Reza, T. Nalugwa, K. Farr, M. Nantale, D. Oyuku, Annet Nakaweesa, J. Musinguzi, et al. “Study Protocol: A Cluster Randomized Trial to Evaluate the Effectiveness and Implementation of Onsite GeneXpert Testing at Community Health Centers in Uganda (XPEL-TB).” Implementation Science, 2020.
T. V. D. Handel, K. H. Hampton, Ian Sanne, Wendy S. Stevens, R. Crous, and A. V. Rie. “The Impact of Xpert(®) MTB/RIF in Sparsely Populated Rural Settings.” The International Journal of Tuberculosis and Lung Disease, 2015.
V. Mittal, Manoj Kumar, and Ajay Kumar Singh. “TB LAMP Assay, a Beneficial Tool for the Diagnosis of Tubercular Meningitis in Resource-Limited Settings.” Journal of Infection in Developing Countries, 2024.
V. Nikolayevskyy, V. Nikolayevskyy, I. Kontsevaya, E. Nikolaevskaya, E. Surkova, S. Samchenko, and S. Esipenko. “Diagnostic Performance and Impact of Routinely Implemented Xpert® MTB/RIF Assay in a Setting of High Incidence of Drug-Resistant TB in Odessa Oblast, Ukraine.” Clinical Microbiology and Infection, 2019.
Y. R. Ngangue, Cyrille Mbuli, Angela Neh, Emmanuel Nshom, Armand Koudjou, Dennis A. Palmer, Norah Nyah Ndi, et al. “Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis Among Hospital Outpatients in Cameroon.” Journal of Clinical Microbiology, 2022.
Youngwhan Kim, M. Seong, Taek Soo Kim, C. Yoo, Han Sk, and J. Yim. “Evaluation of Xpert(®) MTB/RIF Assay: Diagnosis and Treatment Outcomes in Rifampicin-Resistant Tuberculosis.” The International Journal of Tuberculosis and Lung Disease, 2015.
Z. Burger, H. Aung, M. Seifert, T. T. Mar, V. Harris, R. Colman, T. Rodwell, and S. Aung. “Contributions of GeneXpert® to TB Diagnosis in Myanmar.” The International Journal of Tuberculosis and Lung Disease, 2022.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Yudha Viantoro, Fifa Yuniarmi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
